After scoring big Pfizer buyout, a Therachon co-founder turns once again to dwarfism with $24M Series A

Less than two years after selling her first biotech to Pfizer for a hefty $810 million, a French researcher has launched a new gene therapy outfit that’s focusing on the same target — dwarfism — but taking a different path to treatment.

The scientist is Elvire Gouze and the company is InnoSkel, which launched with €20 million in Series A financing (about $24.2 million) early Monday. Though InnoSkel is aiming to treat a whole host of rare skeletal diseases that affect the body’s collagen, it’s first going after what’s known as spondyloepiphyseal dysplasia congenita (SEDc), the second-leading cause of dwarfism that stunts the growth of a patient’s cartilage.